Cyclooxygenases 1 and 2

Annual Review of Pharmacology and Toxicology

Volumn 38, Issue , 1998, Pages 97-120

  Vane, J R ^a   Bakhle, Y S ^a,b   Botting, R M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Inflammation; Nonsteroidal anti inflammatory drugs; Prostaglandins; Selective inhibitors

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; 6 METHOXY 2 NAPHTHYLACETIC ACID; ACETYLSALICYLIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DICLOFENAC; ETODOLAC; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN E2; ROFECOXIB; RS 57067000; SULINDAC; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CHILDBIRTH; CLINICAL TRIAL; COLORECTAL CANCER; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME ACTIVITY; FEVER; GENE DELETION; HUMAN; HYPERALGESIA; INFLAMMATION; KIDNEY; NONHUMAN; OSTEOARTHRITIS; PREGNANCY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; STOMACH; THROMBOCYTE;

BACTERIA (MICROORGANISMS);

EID: 0031777185     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.38.1.97     Document Type: Review

References (127)

1. DeWitt DL, Smith WL. 1988. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl. Acad. Sci. USA 85:1412-16
2. Merlie JP, Fagan D, Mudd J, Needleman P. 1988. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J. Biol. Chem. 263:3550-53
3. Yokoyama C, Takai T, Tanabe T. 1988. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett. 231:347-51
4. Otto JC, Smith WL. 1995. Prostaglandin endoperoxide synthases-1 and -2. J. Lipid Mediat. Cell Signal. 12:139-56
5. Herschman HR. 1996. Prostaglandin synthase 2. Biochim. Biophys. Acta 1299: 125-40
6. Bakhle YS, Botting RM. 1996. Cyclooxygenase-2 and its regulation in inflammation. Mediat. Inflamm. 5:305-23
7. Jouzeau J-Y, Terlain B, Abid A, Nedelec E, Netter P. 1997. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563-82
8. Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231:232-35
9. Luong C, Miller A, Barnett J, Chow J, Ramesha C, et al. 1996. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 3:927-33
10. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, et al. 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-48
11. 2 synthase-1. Nature 367:243-49
12. Mancini JA, O'Neill GP, Bayly C, Vickers PJ. 1994. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett. 342:33-37
13. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. 1994. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 269:13207-15
14. O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, et al. 1994. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol. Pharmacol. 45:245-54
15. Griswold DE, Adams JL. 1996. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med. Res. Rev. 16:181-206
16. 523 to Val mutation. J. Biol. Chem. 272:9280-86
17. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, et al. 1996. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 271: 15810-14
18. 509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J. Biol. Chem. 271:19134-39
19. Mancini JA, Riendeau D, Falgueyret JP, Vickers PJ, O'Neill GP. 1995. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 270:29372-77
20. Bhattacharyya DK, Lecomte M, Rieke CJ, Garavito RM, Smith WL. 1996. Involvement of arginine 120, glutamate 524 and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J. Biol. Chem. 271:2179-84
21. Ren Y, Loose-Mitchell DS, Kulmacz RJ. 1995. Prostaglandin H synthase-1: evaluation of C-terminus function. Arch. Biochem. Biophys. 316:751-57
22. Ren Y, Walker C, Loose-Mitchell DS, Deng J, Ruan K-H, et al. 1995. Topology of prostaglandin H synthase-1 in the endoplasmic reticulum membrane. Arch. Biochem. Biophys. 323:205-14
23. Regier MK, DeWitt DL, Schindler MS, Smith WL. 1993. Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. Arch. Biochem. Biophys. 301:439-44
24. Monta I, Schindler MS, Regier MK, Otto JC, Hori T, et al. 1995. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270:10902-8
25. Otto JC, Smith WL. 1994. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J. Biol. Chem. 269:19868-75
26. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, et al. 1996. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol. 156:758-64
27. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, et al. 1996. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology 111:445-54
28. Cohn SM, Schloemann S, Tessner T, Seibert K, Stenson WF. 1997. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest. 99:1367-79
29. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. 1997. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276-80
30. Vane JR, Botting RM. 1994. Biological properties of cyclooxygenase products. In Lipid Mediators, ed. F Cunningham, pp. 61-97. London: Academic
31. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, et al. 1994. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94:2504-10
32. 2 on the induction of nitric oxide- and prostanoid-forming pathways in cultured rat mesangial cells. Biochem. J. 313:617-23
33. Antiplatelet Trialists' Collaboration. 1994. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:81-106
34. Förster W, Parratt JR. 1996. The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low? Cardiovasc. Drugs Ther. 10:727-34
35. Sawdy R, Slater D, Fisk N, Edmonds DK, Bennett P. 1997. Use of a cyclo-oxygenase type-2-selective nonsteroidal anti-inflammatory agent to prevent preterm delivery. Lancet 350:265-66
36. Gibb W, Sun M. 1996. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J. Endocrinol. 150:497-503
37. Trautman MS, Edwin SS, Collmer D, Dudley DJ, Simmons D, Mitchell MD. 1996. Prostaglandin H synthase-2 in human gestational tissues: regulation in amnion. Placenta 17:239-45
38. Toth P, Li X, Lei ZM, Rao CV. 1996. Expression of human chorionic gonadotropin (hCG)/luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes. J. Clin. Endocrinol. Metab. 81:1283-88
39. Chakraborty I, Das SK, Wang J, Dey SK. 1996. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol. 16:107-22
40. Zakar T, Hirst JJ, Milovic JE, Olson DM. 1995. Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells. Endocrinology 136:1610-19
41. Spaziani EP, Lantz ME, Benoit RR, O'Brien WF. 1996. The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4. Prostaglandins 51:215-23
42. McLaren WJ, Young IR, Wong MH, Rice GE. 1996. Expression of prostaglandin G/H synthase-1 and -2 in ovine amnion and placenta following glucocorticoid-induced labour onset. J. Endocrinol. 151:125-35
43. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, et al. 1995. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-92
44. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, et al. 1995. Prostaglandin synthase 2 gene disruption casuses severe renal pathology in the mouse. Cell 83:473-82
45. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, et al. 1995. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406-9
46. Richards JS, Fitzpatrick SL, Clemens JW, Morris JK, Alliston T, et al. 1995. Ovarian cell differentiation: a cascade of multiple hormones, cellular signals, and regulated genes. [Review]. Rec. Prog. Hormone Res. 50:223-54
47. DeWitt DL, Smith WL. 1995. Yes, but do they still get headaches? Cell 83:345-48
48. Mahler JF, Davis BJ, Morham SG, Langenbach R. 1996. Disruption of cyclooxygenase genes in mice. Toxicol. Pathol. 24:717-19
49. Yamagata K, Andreassson KI, Kaufman WE, Barnes CA, Worley PF. 1993. Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorticoids. Neuron 11:371-86
50. Breder CD, Dewitt D, Kraig RP. 1995. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355:296-315
51. Breder CD, Saper CB. 1996. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res. 713:64-69
52. Jones SA, Adamson SL, Bishai I, Lees J, Engelberts D, Coceani F. 1993. Eicosanoids in third ventricular cerebrospinal fluid of fetal and newborn sheep. Am. J. Physiol. 264:R135-42
53. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. 1996. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 390:165-69
54. O'Neill GP, Ford-Hutchinson AW. 1993. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:156-60
55. Urade Y, Kitahama K, Ohishi H, Kaneko T, Mizuno N, et al. 1993. Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus and oligodendrocytes of the adult rat brain. Proc. Natl. Acad. Sci. USA 90:9070-74
56. Blatteis CM, Sehic E. 1997. Fever: How may circulating pyrogens signal the brain? News Physiol. Sci. 12:1-8
57. Cao C, Matsumura K, Yamagata K, Watanabe Y. 1996. Endothelial cells of the brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: a possible site of prostaglandin synthesis responsible for fever. Brain Res. 733:263-72
58. Elmquist JK, Breder CD, Sherin JE, Scammell TE, Hickey WF, et al. 1997. Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. J. Comp. Neurol. 382:119-29
59. Cao C, Matsumura K, Yamagata K, Watanabe Y. 1997. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in rat brain. Am. J. Physiol. 272:R1712-25
60. Ferreira SH. 1972. Prostaglandins, aspirin-like drugs and hyperalgesia. Nature 240:200-3
61. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. 1997. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α. Br. J. Pharmacol. 121: 417-24
62. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. 1991. Interleukin 8 as a mediator of sympathetic pain. Br. J. Pharmacol. 104:765-67
63. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. 1992. The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 107:660-64
64. 2-induced hyperalgesia in conscious mice. Brain Res. 677:138-44
65. 2 causes sensitization of the primary afferent neuron via the spinal release of glutamate. Inflamm. Res. 45:499-502
66. Malmberg AB, Yaksh TL. 1992. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257:1276-79
67. Yamamoto T, Nozaki-Taguchi N. 1996. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res. 739:104-10
68. Gardiner NJ, Giblett S, Grubb BD. 1997. Cyclooxygenases in rat spinal cord: selective induction of COX-2 during peripheral inflammation. Br. J. Pharmacol, 120:71P (Abstr.)
69. Willingale HL, Gardiner NJ, McLymont N, Giblett S, Grubb BD. 1997. Prostanoids synthesized by cyclooxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br. J. Pharmacol. In press
70. 2. J. Lipid Mediat. Cell Signal. 12:443-48
71. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-19
72. 2 is a ligand for the adipocyte determination factor PPARgamma. Cell 83:803-12
73. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83:841-50
74. 2 in human hepatocarcinoma SK-HEP-1 cells. FEBS Lett. 368:348-52
75. Prescott SM, White RL. 1996. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87:783-86
76. Tsujii M, Dubois RN. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501
77. Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL. 1995. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 92:7961-65
78. Bennett A, Berti F, Ferreira SH. 1993. Nimesulide; a multifactorial therapeutic approach to the inflammatory process?; a 7-year clinical experience. Drugs 46:1-283
79. Furst DE. 1997. Meloxicam: selective COX-2 inhibition in clinical practice. In Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, ed. JR Vane, JH Botting. London: Kluwer/William Harvey Press. In press
80. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, et al. 1997. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med. Chem. 40:1347-65
81. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, et al. 1997. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:105-17
82. Lanza F, Simon T, Quan H, Bolognese J, Rack MF, et al. 1997. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg q.i.d. or ibuprofen (IBU) 800 mg t.i.d. Gastroenterology 112:A194 (Abstr.)
83. Lanza FL, Rack MF, Callison DA, Hubbard RC, Yu SS, et al. 1997. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology 112:A194 (Abstr.)
84. Hubbard RC, Mehlisch DR, Jasper DR, Nugent MJ, Yu S, et al. 1996. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J. Invest. Med. 44:293A (Abstr.)
85. Ehrich E, Mehlisch D, Perkins S, Brown P, Wittreich J, et al. 1996. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum. 39(Suppl. 9):S81 (Abstr.)
86. Chan C-C, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, et al. 1995. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J. Pharmacol. Exp. Ther. 274:1531-37
87. Stenson WF. 1997. Cyclooxygenase 2 and wound healing in the stomach. Gastroenterology 112:645-48
88. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, et al. 1997. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-97
89. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-70
90. Giovanucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, et al. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:609-14
91. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. 1996. Aspirin use and risk of fatal cancer. Cancer Res. 53:1322-27
92. Giovanucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, et al. 1994. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121:241-46
93. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, et al. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1313-16
94. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, et al. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-88
95. delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-9
96. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. 1997. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 57:1301-5
97. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. 1997. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 40:344-49
98. Ford-Hutchinson AW. 1997. New highly selective COX-2 inhibitors. In Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, ed. JR Vane, JH Botting. London: Kluwer/William Harvey Press. In press
99. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. 1997. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 10:503-7
100. Noguchi M, Earashi M, Minami M, Miyazaki I, Tanaka M, Sasaki T. 1995. Effects of piroxicam and esculetin on the MDA-MB-231 human breast cancer cell line. Prostaglandin Leukot. Essent. Fatty Acids 53:325-29
101. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, et al. 1997. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:267-71
102. Cochran FR, Vitek MP. 1996. Neuroinflammatory mechanisms in Alzheimer's disease: new opportunities for drug discovery. Expert Opin. Invest. Drugs 5:449-55
103. Breitner JCS. 1996. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:401-11
104. McGeer PL, McGeer EG. 1995. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:195-218
105. Stewart WF, Kawas C, Corrada M, Metter EJ. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-32
106. Hampel H, Muller N. 1995. Inflammatory and immunological mechanisms in Alzheimer's disease. Drug News Perspect. 8:599-608
107. Bauer MKA, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Haerter PJ, et al. 1997. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 243:726-31
108. Chang JW, Coleman PD, O'Banion MK. 1996. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol. Aging. 17:801-8
109. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-11
110. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90:11693-97
111. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. 1997. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Physiol. Pharmacol. 48:In press
112. Meade EA, Smith WL, DeWitt DL. 1993. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J. Biol. Chem. 268:6610-14
113. Engelhardt G, Bögel R, Schnitzer Chr, Utzmann R. 1996 Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem. Pharmacol. 51:21-28
114. Klein T, Nüsing RM, Pfeilschifter J, Ullrich V. 1994. Selective inhibition of cyclooxygenase 2. Biochem. Pharmacol. 48:1605-10
115. Futaki N, Takahashi S, Yokoyama M, Arai S, Higuchi S, Otomo S. 1994. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55-59
116. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD and Smith WL. 1994. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271:927-34
117. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, et al. 1995. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305:479-84
118. Churchill L, Graham AG, Shih C-K, Pauletti D, Farina PR, Grob PM. 1996. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 4:125-35
119. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, et al. 1994. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271:1705-12
120. 2 production. Inflamm. Res. 45:246-53
121. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, et al. 1995. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 45:68-74
122. Warner TD, Amirmansour C, Vane JR. 1995. Nimesulide: selectivity for cyclooxygenase 2 over cyclo-oxygenase 1. Inflamm. Res. 44(Suppl 3):S274 (Abstr.)
123. Vane JR, Botting RM. 1996. The history of anti-inflammatory drugs and their mechanism of action. In New Targets in Inflammation - Inhibitors of COX-2 or Adhesion Molecules, ed. N Bazan, J Botting, JR Vane, pp. 1-12. London: Kluwer/William Harvey Press
124. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, et al. 1994. Purification, characterzation and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim. Biophys. Acta 1209:130-39
125. Cromlish WA, Kennedy BP. 1996. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Biochem. Pharmacol. 52:1777-85
126. Carabaza A, Cabre F, Rottlan E, Calvo L, Gutierrez M, Gomez M, et al. 1996. Effect of COX-2 inhibitors on constitutive and inducible cyclooxygenase activity from different sources. Comparison with anti-inflammatory activity. Prostaglandins Leukot. Essent. Fatty Acids 55(Suppl. 1):93 (Abstr.)
127. Glaser K, Sung M-L, O'Neill K, Belfast M, Hartman D, et al. 1995. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol. 281:107-11